Case report: Reoperative parathyroidectomy for large ectopic hyperplastic parathyroid in the mediastinum of a patient with recurrent secondary hyperparathyroidism

Yong Lv†, Qiuyuan Wang‡, Ling Zhang‡, Qing Zhou†, Zhiyu Mi†, Yi Wu† and Jingning Cheng†

†Department of Otolaryngology-Head and Neck Surgery, China-Japan Friendship Hospital, Beijing, China, ‡Department of Orthopaedic Surgery, China-Japan Friendship Hospital, Beijing, China, †Graduate School of Beijing University of Chinese Medicine, Beijing, China, ‡Department of Nephrology, China-Japan Friendship Hospital, Beijing, China

Introduction: Secondary hyperparathyroidism (SHPT) is a common complication in hemodialysis patients with chronic renal failure uremia. For severe SHPT, parathyroidectomy is effective. Owing to the variability in parathyroid anatomy, surgical parathyroidectomy can be complex and many patients experience recurrent SHPT, which may require repeated surgery. These cases pose significant challenges to surgeons.

Case description: An elderly woman with recurrent severe SHPT was admitted to our hospital. Preoperative methoxyisobutylisonitrile (MIBI) examination found a large ectopic parathyroid gland in the superior mediastinum, and she underwent reoperative parathyroidectomy. A large parathyroid gland in the right anterior mediastinum and another parathyroid gland in the left lingual lobe of the thymus were removed. The patient had postoperative hypocalcemia that was successfully corrected with calcium supplementation via femoral vein catheterization. During the 1-year postoperative follow-up, the patient’s iPTH was well controlled and her blood calcium was within the normal range.

Conclusion: We report a case of parathyroidectomy to remove multifocal ectopic hyperplastic parathyroid tissue in the mediastinum. Preoperative MIBI accurately detected the lesions. Calcium supplementation via femoral vein catheterization successfully corrected postoperative hypocalcemia. Postoperative follow-up for 1 year indicated that the surgery was successful.

KEYWORDS
reoperative parathyroidectomy, secondary hyperparathyroidism, chronic renal failure (CRF), hemodialysis, hypocalcemia, iPTH

Introduction

Secondary hyperparathyroidism (SHPT) is a common complication in hemodialysis patients with chronic renal failure uremia (1). Chronic renal failure leads to long-term dysregulation of calcium–phosphorus metabolism, a compensatory increase in parathyroid hormone (PTH) secretion, and parathyroid hyperplasia. Drug therapy can
be used to treat early-stage SHPT (2, 3). Calcimimetic is a popular treatment choice for managing SHPT patients (4, 5). However, for severe SHPT and patients with drug resistance, surgical treatment is required (6–8). This article presents a complex reoperative case of parathyroidectomy for multifocal large ectopic hyperplastic parathyroid tissue in a hemodialysis patient with recurrent SHPT.

Case description

Patient history

A 69-year-old woman was admitted to our hospital for persistent bone pain, weakness, and skin pruritus. She had been diagnosed with chronic renal insufficiency more than 30 years prior to her presentation. Twelve years prior to the presentation, she began regular hemodialysis three times per week. Five years before the presentation, she began to experience symptoms of bone pain, weakness, and skin pruritus. She visited a local hospital, and the clinicians found an elevated iPTH (above 2,000 pg/ml). The patient then received parathyroidectomy surgery in that hospital, during which three parathyroid glands were identified and removed intraoperatively (according to the patient’s statement; surgical notes were not provided). Unfortunately, although her iPTH decreased postoperatively, it remained higher than normal (up to 1,000 pg/ml). The patient took Rocaltrol after surgery, but her iPTH level did not decrease; in contrast, it gradually increased. After 1 year of surgery, the highest iPTH level was 3,000 mg/ml. The patient continued to take Rocaltrol, but her iPTH level continued to worsen. One month before admission to our hospital, her iPTH was up to 4,000 pg/ml according to laboratory tests performed at her local hospital.

Diagnostic assessment

After admission to our hospital, a parathyroid ultrasound indicated a hypoechoic nodule on the left side of the suprasternal fossa (Figure 1). Methoxyisobutylisonitrile (MIBI) examination showed a 3.2 cm × 3.0 cm soft tissue density nodule accompanied by eggshell calcification in the superior mediastinum, located behind the innominate artery and beside the trachea (Figures 2A, B). MIBI also showed an approximately 1.2 cm × 1.0 cm soft tissue density nodule in the suprasternal fossa (Figures 2C, D). The MIBI scans of the two foci were all high uptake. Preoperative blood biochemistry analysis showed that the iPTH was above 3,000 pg/ml, calcium was 2.24 mmol/L, phosphorus was 1.46 mmol/L, and alkaline phosphatase (ALP) was 452 IU/L.
Therapeutic interventions

Bedside hemodialysis was arranged 1 day prior to the planned parathyroidectomy surgery. Under general anesthesia, the patient underwent a second parathyroidectomy via an anterior transcervical low-neck incision. After routine isolation through the subcutaneous tissue and adhered scar tissue, structures such as the trachea in the root of the neck, the cervical transverse arteries and veins, and the thymic tongue lobe were preserved. Taking particular care to protect the blood vessels of the root of the neck, we advanced a probe along the right side of the trachea to the upper mediastinum. The mass was probed near the trachea, above the aortic arch. The blood vessels around the mass were carefully separated and transected by electrocoagulation hemostasis. We gradually separated the mass from surrounding tissue and protected the capsule so it could remain as intact as possible during the parathyroidectomy. However, due to the large size of the mass, the capsule broke during removal. We removed the lump intact, and no macroscopically visible ectopic parathyroid tissue remained. The surgical site was irrigated with copious amounts of normal saline to prevent implantation of any exfoliated tumor cells. Intraoperatively, we also removed a very large parathyroid gland in the right anterior mediastinum. This second mass was 7 cm × 3.5 cm in size and weighed 23.72 g (Figures 3A, B). We also removed another parathyroid gland in the left lingual lobe of the thymus. The diameter of the third mass was 1 cm, and its weight was 0.69 g. No injury was found when exploring the bilateral recurrent laryngeal nerve. Furthermore, we used a nerve monitor to measure the electrical potential of the recurrent laryngeal nerve (V2, R2) and found no significant change before and after removing the parathyroids. Finally, we placed a drainage tube, sutured the soft tissue, and closed the wound.

The patient returned to the ward safely after recovery from anesthesia. An immediate postoperative blood test showed that iPTH had decreased to 102.7 pg/ml. Postoperatively, the patient reported that her symptoms of bone pain, weakness, and skin

![FIGURE 2](image_url)

MIBI examination. (A, B) Large soft tissue density nodule accompanied by eggshell calcification in the superior mediastinum, located behind the innominate artery and beside the trachea. (C, D) soft tissue density nodule in the suprasternal fossa.

---

Frontiers in Surgery 03 frontiersin.org
pruritus were significantly reduced. One day after surgery, the patient underwent bedside hemodialysis. The postoperative blood electrolyte analysis indicated hypocalcemia (blood calcium was 1.69 mmol/L). The patient felt numbness and acantheesthesia in her fingers. We treated her with 30 g intravenous calcium gluconate diluted in 300 ml of 0.9% NS via femoral vein catheterization. On the second day of postsurgery, the patient’s blood calcium recovered to 2.6 mmol/L and the iPTH decreased to 88.79 pg/ml. The numbness and acantheesthesia in her fingers also disappeared, so we stopped the intravenous calcium treatment. The patient was discharged from our hospital on the third day post-surgery and continued oral calcium and calcitriol supplementation (calcium carbonate 1 g TID and calcitriol 2 g BID). During 1-year follow-up, the patient’s iPTH was well controlled and the blood calcium remained within normal limits (Figure 4).

Discussion

Regarding surgical indication, the patient had received regular hemodialysis for 12 years and had developed SHPT at least 5 years prior to presentation. Although she had previously undergone a parathyroidectomy, her postoperative iPTH had remained elevated (1,000 pg/ml) and gradually increased over time. This indicated the continued presence of

FIGURE 3
Large parathyroid in the right anterior mediastinum after removal. (A) Length of the mass was approximately 7 cm; (B) width was approximately 3.5 cm.

FIGURE 4
Results of the 1-year follow-up. (A) iPTH level; (B) blood calcium level.
parathyroid tissue with excessive parathyroid hormone secretion, suggesting incomplete removal of parathyroid tissue in the primary surgery. The maximum iPTH level of this patient was above 4,000 pg/ml. Such a high iPTH level can significantly exacerbate the dysregulated mineral and bone metabolism associated with chronic renal insufficiency and further affect the cardiovascular system, as well as the central and peripheral nervous system (9–12). Drug therapy alone could not control the worsening parathyroid hyperplasia and the severe clinical symptoms in our patient. Therefore, reoperative parathyroidectomy was the best choice for this patient.

Accurate imaging is crucial for successful reoperative parathyroidectomy (14, 15). This case highlights the diagnostic value of the MIBI examination for ectopic parathyroid detection. In this case, the initial parathyroid ultrasound examination did not find the large ectopic parathyroid in the superior mediastinum, but the MIBI did. Although the benefits that MIBI provides in cases of parathyroidectomy for SHPT are still controversial (14, 16–19), we suggest that for complex SHPT cases, especially reoperative cases, MIBI examination can help clinicians avoid missed diagnoses and improve preoperative planning.

As a reoperative parathyroidectomy surgery, the main goal, in this case, was to find and remove all remaining parathyroid tissue (13). This also became the biggest challenge during the surgery. The preoperative MIBI found a large ectopic parathyroid located deep in the superior mediastinum. This location made it challenging to expose the target lesions through the common anterior transcervical approach. Excellent surgical skills and familiarity with anatomy were required for the surgeons to complete the surgery successfully. Intraoperatively, it was necessary to pay close attention to blood vessel protection and operate as bloodlessly as possible because once mediastinal hemorrhage occurs, hemostasis is very difficult. These aspects all required a higher standard of delicate surgical skills.

Postoperative management is also crucial for SHPT patients (20, 21). This case shows that clinicians need to closely monitor patients’ blood calcium to promptly discover and treat hypocalemia (6, 22). In recent years, the mode of multidisciplinary team (MDT) management has been introduced into the treatment of SHPT patients (23, 24). Since SHPT treatment is a long-term project, patient management should be both whole-process and comprehensive (20, 25). Postoperative follow-up is an important component of patient care.

**Conclusion**

We report a case of reoperative parathyroidectomy for multifocal large ectopic hyperplastic parathyroid tissue within the mediastinum of a patient with recurrent SHPT. Preoperative MIBI accurately detected the lesions. Calcium supplementation via femoral vein catheterization successfully corrected postoperative hypocalcemia. One-year postoperative follow-up showed that the surgery was successful as the patient’s iPTH remained well controlled and her blood calcium remained within the normal range.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author/s.

**Ethics statement**

Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

YL and QYW wrote the manuscript. QZ, YW, and MZY collect the data of the case. LZ and JNC conducted the postoperative follow-up and revised the manuscript. YL and QYW contributed equally to this article and are co-first authors. All authors contributed to the article and approved the submitted version.

**Acknowledgments**

The authors thank Leah Cannon, Ph.D., from Liwen Bianji (Edanz) (www.liwenbianji.cn/), for editing the English text of a draft of this manuscript.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Bellorin-Font E, Vasques-Rozo G, Martin KJ. Controversies in the management of secondary hyperparathyroidism. *Curr Osteoporos Rep*. (2019) 17(5):333–42. doi: 10.1007/s11914-019-00533-x

2. Sr HE, Eledrisi M, Khan F, Elouayy AY. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. *Cureus*. (2021) 13(7):e16388. doi: 10.7759/cureus.16388

3. Portillo MR, Rodríguez-Ortiz ME. Secondary hyperparathyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. *Rev Endocr Metab Disord*. (2017) 18(1):79–95. doi: 10.1007/s11154-017-9421-4

4. Sun Y, Tian B, Sheng Z, Wan P, Xu T, Yao L. Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis. *BMC Nephrol*. (2020) 21(1):316. doi: 10.1186/s12882-019-1639-9

5. Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruooso M, Strippoli G. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis. *Am J Kidney Dis*. (2020) 76(3):321–30. doi: 10.1053/j.ajkd.2020.02.439

6. Steindl GK, Kuo JH. Surgical management of secondary hyperparathyroidism. *Kidney Int Rep*. (2021) 6(2):254–64. doi: 10.1016/j.ekir.2020.11.023

7. van der Plas WY, Nolette ME, van Ginthoven TM, Kruijff S. Secondary and tertiary hyperparathyroidism: a narrative review. *Scand J Surg*. (2020) 109(4):271–8. doi: 10.1177/1475469619866015

8. Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al. Surgical management of secondary hyperparathyroidism versus cinacalcet among patients undergoing hemodialysis. *J Clin Endocrinol Metab*. (2022) 107(7):2016–25. doi: 10.1210/clinemed/dgac142

9. Gao Z, Li X, Mao J, Lun L. Impacts of parathyroidectomy on calcium and phosphorus metabolism disorder, arterial calcification and arterial stiffness in haemodialysis patients. *Asian J Surg*. (2019) 42(1):6–10. doi: 10.1016/j.asjsur.2018.04.001

10. Reiss AB, Miyawaki N, Moon J, Kaselman LJ, Voloshyna I, D’Avino Jr R, et al. CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. *Atherosclerosis*. (2018) 278:47–59. doi: 10.1016/j.atherosclerosis.2018.08.046

11. Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromsoe study. *J Neurol*. (2006) 253(4):464–70. doi: 10.1007/s00415-005-0027-5

12. Ahmadmehrabi S, Tang W. Hemodialysis-induced cardiovascular disease. *Semin Dial*. (2018) 31(3):258–67. doi: 10.1111/ Hed.12694

13. Simental A, Ferris RL. Reoperative parathyroidectomy. *Otolaryngol Clin North Am*. (2008) 41(6):1269–74. xii. doi: 10.1016/j. otcl.2008.05.008

14. Camenzuli C, DeMarco AN, Isaacs KE, Grant Y, Jackson J, Alasfi A, et al. The changing face of reoperative parathyroidectomy: a single-centre comparison of 147 parathyroid reoperations. *Ann R Coll Surg Engl*. (2021) 103(1):29–34. doi: 10.1308/rcsann.2020.0185

15. Zolin SJ, Crawford K, Rudin AV, Harsono H, Krishnamurthy VD, Jin J, et al. Selective parathyroid venous sampling in reoperative parathyroid surgery: a key localization tool when noninvasive tests are unrevealing. *Surgery*. (2021) 169(1):126–32. doi: 10.1016/s0039-6010(20)31888-9

16. Ramonell KM, Chen H, Lindeman B, Fazendin J. Re-operative parathyroidectomy: how many positive localization studies are required. *Am J Surg*. (2021) 222(2):485–8. doi: 10.1016/j.amjsurg.2020.11.027

17. Frey S, Couette C, Trésallet C, Hamy A, Caillard C, Blanchard C, et al. Utility of a second (99 m) Tc-MIBI scintigraphy before reoperation for patients with persistent sporadic primary hyperparathyroidism: results of a retrospective multicenter study. *Ann Surg Oncol*. (2020) 27(10):3831–9. doi: 10.1245/s10434-020-08428-3

18. Parikh AM, Grogan RH, Morin FE. Localization of parathyroid disease in reoperative patients with primary hyperparathyroidism. *Int J Endocrinol*. (2020) 2020:9649564. doi: 10.1155/2020/9649564

19. Jones BA, Lindeman B, Chen H. Are Tc-99m-sestamibi scans in patients with secondary hyperparathyroidism and renal failure needed. *J Surg Res*. (2019) 243:380–3. doi: 10.1016/j.jss.2019.04.084

20. Kakani E, Sloan D, Sawaya BP, El-Husseini A, Mallick HH, Rao M. Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient. *Semin Dial*. (2019) 32(6):541–52. doi: 10.1111/SD.12883

21. Eidman KE, Wetmore JB. The role of parathyroidectomy in the management of secondary hyperparathyroidism. *Curr Opin Nephrol Hypertens*. (2017) 26(6):516–22. doi: 10.1097/MNH.0000000000000365

22. Gao D, Lou Y, Cui Y, Liu S, Cui W, Sun G. Risk factors for hypocalcemia in dialysis patients with refractory secondary hyperparathyroidism after parathyroidectomy: a meta-analysis. *Ren Fail*. (2022) 44(1):503–12. doi: 10.1080/ 0886022X.2022.2048856

23. Hancox SH, Sinnott JD, Kirkland P, Lipscomb D, Owens E, Howlett DC. Setting up a parathyroid multidisciplinary team meeting: one year’s experience, outcomes and learning points. *J Laryngol Otol*. (2018) 132(5):252–6. doi: 10.1017/S002221511800108X

24. Casey J, Li CH, Johnson V, Shuman C, McClelland P. Multidisciplinary approach for prescriptive management of mineral and bone metabolism in chronic kidney disease: development of a dietetic led protocol. *J Ren Care*. (2006) 32(4):187–91. doi: 10.1111/j.1755-6686.2006.tb00200.x

25. Galassi A, Ciceri P, Fasulo E, Carugo S, Cianciolo G, Cozzolino M. Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly. *Drugs Aging*. (2019) 36(10):885–95. doi: 10.1007/ s40266-019-00966-3